CASI Pharmaceuticals Announces Appointment Of Main Economical Officer
3 min readROCKVILLE, Md., and BEIJING, Dec. 16, 2020 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on producing and commercializing innovative therapeutics and pharmaceutical products, right now announces the appointment of Weihao Xu to the situation of Main Financial Officer. Mr. Xu will report to Dr. Wei-Wu He, Chairman and CEO of CASI.
Most recently, in January 2020, Mr. Xu founded and served as Main Financial investment Officer for Permanence Cash LLC, a healthcare-committed investment agency. From February 2018 till March 2019, he served as Chief Financial Officer for 111, Inc. a Shanghai-centered digital healthcare organization, in which he led the initial public giving of the business on NASDAQ, and oversaw the company’s monetary functions, corporate approach and trader relations. Prior to that, Mr. Xu served as a portfolio supervisor and investment analyst at Matthews International Capital Management LLC, a San Francisco-primarily based expense agency focusing on investing in Asia, from 2016 to 2018 and subsequently from 2019 to 2020. He also served as head of emerging markets and portfolio supervisor in New York at Permal Asset Management LLC from 2014 to 2016 and investment analyst in London at Lansdowne Companions from 2012 to 2014. Mr. Xu retains a Master of Philosophy diploma in Accounting from Columbia Business College.
“We are quite delighted to welcome Weihao to our management group. His exclusive working experience encompasses both equally that of a healthcare-focused acquire-side professional and of a CFO overseeing money operations, together with regions of money scheduling and fundraising. These competencies will allow him to appreciably contribute to driving a variety of our planned strategic initiatives ahead in 2021 and past,” mentioned Dr. He.
About CASI Pharmaceuticals
CASI Prescribed drugs, Inc. (“CASI” or the “Enterprise”) is a U.S. biopharmaceutical firm targeted on developing and commercializing modern therapeutics and pharmaceutical products and solutions in China, the United States, and all over the planet. The Enterprise is centered on buying, establishing and commercializing goods that augment its hematology oncology therapeutic concentration as effectively as other regions of unmet health care need to have. The Firm intends to execute its program to grow to be a leader by launching medicines in the increased China current market leveraging the Company’s China-based mostly regulatory and professional competencies and its international drug advancement experience. The Firm’s operations in China are done through its wholly-owned subsidiary, CASI Prescription drugs (China) Co., Ltd., which is located in Beijing, China. The Company has constructed a industrial staff of in excess of 70 hematology and oncology product sales and promoting professionals centered in China. Extra info on CASI is accessible at www.casipharmaceuticals.com.
Ahead-Hunting Statements
This news release includes forward-seeking statements within the indicating of the Personal Securities Litigation Reform Act with regard to the outlook for anticipations for upcoming economical or company general performance, revenue growth, approaches, expectations and objectives. Ahead-looking statements are topic to various assumptions, risks and uncertainties, which improve more than time. Forward-on the lookout statements discuss only as of the day they are made, and we believe no obligation to update ahead-seeking statements. New components arise from time to time, and it is not possible for us to forecast which aspects will crop up. In addition, we can’t assess the influence of every issue on our company or the extent to which any issue, or mix of factors, may possibly result in precise effects to differ materially from all those contained in any forward-looking statements. True effects could differ materially from people currently predicted owing to a quantity of components.
Resource CASI Pharmaceuticals, Inc.
